Search
SOLACI Congress
HomeCONGRESSInternational Congresses

International Congresses

View Category
Day 3

OPTIMIZE: 3 months versus 12 months of dual anti-aggregation with zotarolimus-eluting stents

The current recommendation for dual anti-aggregation post-DES implantation is 12 months. However, the ideal length for specific...
solaci -
Learn More
Day 4

PRIMA: Closure of patent foramen ovale in patients with migraine with aura refractory

It is hypothesized that the presence of a right-left shunt can trigger migraine attacks. The aim of...
solaci -
Learn More
Day 4

SYMPLICITY FLEX: Renal sympathetic denervation in patients with resistant hypertension

Mild refractory hypertension patients were defined as those with daytime systolic BP 135-149 and diastolic BP 90-94...
solaci -
Learn More
Day 4

I-LOVE-IT2: Drug-eluting stents with a permanent polymer versus biodegradable in the same cobalt chromium platform

There is no strong evidence in the literature that the polymer type isolated (permanent or degradable) influences...
solaci -
Learn More
Day 3

SECURITY: 6 months versus 12 months of dual anti-aggregation using 2nd generation DES

This multicenter noninferiority design work included 1399 patients randomized to receive 6 months (n = 682) versus...
solaci -
Learn More
Day 3

VELOCITY: Peritoneal hypothermia in patients undergoing primary angioplasty

There are clinics hypothesis that systemic hypothermia (≤34.9) could reduce infarct size if set before reperfusion. Peritoneal...
solaci -
Learn More
Day 3

TRANSLATE-ACS: One-year prasugrel versus clopidogrel after acute coronary syndrome

Platelet inhibition is critical in reducing atherothrombotic risk in the short and long term after an acute...
solaci -
Learn More
Day 3

ISAR-TRIPLE: 6 weeks versus 6 months of clopidogrel in patients with oral anticoagulation and drug-eluting stent

There are a significant number of patients receiving drug-eluting stents and besides, require oral anticoagulation. The combination...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Dynamic Coronary Roadmap: does it really help reduce contrast use?

Dr. Juan Manuel Pérez - 0
Contrast-induced nephropathy remains a relevant complication of percutaneous coronary interventions (PCI), particularly in patients with multiple comorbidities and complex coronary anatomies. Dynamic Coronary Roadmap...

Endoleaks after endovascular repair of complex aortic aneurysms: always reintervene or monitor with CTA?

Dr. Juan Manuel Pérez - 0
Endovascular repair of thoracoabdominal aneurysms requiring sealing above the renal arteries, with preservation of visceral vessels using fenestrated and/or branched devices (F/B-EVAR), has become...

Is it safe to use negative chronotropic drugs early after TAVI?

Dr. Juan Manuel Pérez - 0
TAVI is associated with a relevant incidence of conduction system disturbances and the development of atrioventricular block that may require permanent pacemaker implantation. Many...

Institutional News

SOLACI Wishes You Happy Holidays

solaci - 0
From the heart, Happy Holidays! The Latin American Society of Interventional Cardiology wishes all its members and the medical community across the continent a very Merry Christmas...

Condolences on the passing of Cristiam Arancibia

solaci - 0
The Latin American Society of Interventional Cardiology deeply mourns the passing of Lic. Cristiam Arancibia, first Director of the Chapter of Technicians and Nurses,...

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy